Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

Immunogenetics

Volumn 50, Issue 3-4, 1999, Pages 201-212

  Sette, Alessandro ^a   Sidney, John ^a  

^a Epimmune   (United States)

Author keywords

Epitopes; HLA; MHC; Polymorphism; Supertypes; Vaccines

Indexed keywords

DNA; HLA A ANTIGEN; HLA A1 ANTIGEN; HLA B ANTIGEN; HLA B27 ANTIGEN;

ALLELE; DNA POLYMORPHISM; ETHNIC GROUP; GENE FREQUENCY; HISTOCOMPATIBILITY GENE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; POPULATION GENETICS; PRIORITY JOURNAL; REVIEW;

EID: 0033388724     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002510050594     Document Type: Review

References (120)

1. Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA (1997) Enhanced immunogenicity of HTV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 94:10856-10861
2. Allen TM, Sidney J, del Guercio M-F, Glickman RL, Lensmeyer GL, Wiebe DA, DeMars R, Pauza CD, Johnson RP, Sette A, Watkins DI (1998) Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol 160:6062-6071
3. An LL, Whitton JL (1997) A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. J Virol 71:2292-2302
4. Barber LD, Gillece Castro B, Percival L, Li X, Clayberger C, Parham P (1995) Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes. Curr Biol 5:179-190
5. Barber LD, Percival L, Arnett KL, Gumperz JE, Chen L, Parham P (1997) Polymorphism in the a1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity. J Immunol 158:1660-1669
6. Barber LD, Percival L, Parham P (1996a) Characterization of the peptide-binding specificity of HLA-B*7301. Tissue Antigens 47:472-477
7. Barber LD, Percival L, Valiante NM, Chen L, Lee C, Gumperz JE, Phillips JH, Lanier LL, Bigge J, Parekh RB, Parham P (1996b) The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. J Exp Med 184:735-740
8. Barouch D, Friede T, Stevanović S, Tussey L, Smith K, Rowland-Jones S, Braud V, McMichael A, Rammensee H-G (1995) HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med 182:1847-1856
9. Bertoletti A, Southwood S, Chesnut R, Sette A, Falco M, Battista Ferrara G, Penna A, Boni C, Fiaccadori F, Ferrari C (1997) Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27 interaction with HLA an T-cell receptor. Hepatology 26:1027-1034
10. Bertoni R, Sette A, Sidney J, Guidotti LG, Shapiro M, Purcell R, Chisari FV (1998) Human class I supertypes and cytotoxic T lymphocyte repertoires extend to chimpanzees. J Immunol 161:4447-4455
11. Bertoni R, Sidney J, Fowler P, Chesnut RW, Chisari FV, Sette A (1997) Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 100:503-513
12. Boisgérault F, Khalil I, Tieng V, Connan F, Tabary T, Cohen JHM, Choppin J, Charron D, Toubert A (1996) Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retinopathy. Proc Natl Acad Sci USA 93:3466-3470
13. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3:205-211
14. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM (1999) Analysis of a successful immune response against hepatitis C virus. Immunity 10:439-449
15. Corr M, Boyd LF, Frankel SR, Kozlowski, S, Padlan EA, Margulies DH (1992) Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of complex. J Exp Med 176:1681-1692
16. Couillin I, Culmann-Penciolelli B, Gomard E, Choppin J, Levy J-P, Guillet J-G, Saragosti S (1994) Impaired CTL recognition due to genetic variations in the main immunogenic region of the HIV-1 nef protein. J Exp Med 180:1129-1134
17. Crook T, Morgenstern JP, Crawford L, Banks L (1989) Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ ras. EMBO J 8:513-519
18. Del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A (1995) Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 154:685-693
19. DiBrino M, Parker KC, Shiloach J, Knierman M, Lukszo J, Turner RV, Biddison WE, Coligan JE (1993a) Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. Proc Natl Acad Sci USA 90:1508-1512
20. DiBrino M, Tsuchida T, Turner RV, Parker KC, Coligan JE, Biddison WE (1993b) HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J Immunol 151:5930-5935
21. DiBrino M, Parker KC, Shiloach J, Turner RV, Tsuchida T, Garfield M, Biddison WE, Coligan JE (1994a) Endogenous peptides with distinct amino acid anchor residue motifs bind to HLA-A1 and HLA-B8. J Immunol 152:620-631
22. DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan JE (1994b) The HLA-B14 peptide binding site can accommodate peptides with different combinations of anchor residues. J Biol Chem 269:32426-32434
23. DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan JE (1995) Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. Biochemistry 34:10130-10138
24. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA (1996) Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 156:3151-3158
25. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, Chesnut RW, Keogh E, Appella E, Nutman TB, Lal AA, Gordon DM, Oloo A, Sette A (1997) Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7:97-112
26. Dumrese T, Stevanović S, Seeger FH, Yamada N, Ishikawa Y, Tokunaga K, Takiguchi M, Rammensee H-G (1998) HLA-A26 subtype A pockets accommodate acidic N-termini of ligands. Immunogenetics 48:350-353
27. Engelhard VH (1994) Structure of peptides associated with MHC class I molecules. Curr Opin Immunol 6:13-23
28. Falk K, Rötzschke O, Stevanović S, Jung G, Rammensee HG (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296
29. Falk K, Rötzschke O, Grahovac B, Schendel D, Stevanović S, Jung G, Rammensee HG (1993) Peptide motifs of HLA-B35 and -B37. Immunogenetics 38:161-162
30. Falk K, Rötzschke O, Takiguchi M, Grahovac B, Gnau V, Stevanović S, Jung G, Rammensee H-G (1994) Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules. Immunogenetics 40:238-241
31. Falk K, Rötzschke O, Takiguchi M, Gnau V, Stevanović S, Jung G, Rammensee HG (1995a) Peptide motifs of HLA-B58, B60, B61, and B62 molecules. Immunogenetics 41:165-168
32. Falk K, Rötzschke O, Takiguchi M, Gnau V, Stevanović S, Jung G, Rammensee HG (1995b) Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behcet's disease. Int Immunol 7:223-228
33. Falk K, Rötzschke O, Takiguchi M, Gnau V, Stevanović S, Jung G, Rammensee HG (1995c) Peptide motifs of HLA-B38 and B39 molecules. Immunogenetics 41:162-164
34. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, Melief CJ, Kast WM (1995) Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 25:2638-2642
35. Fernandez-Viña MA, Falco M, Sun Y, Stastny P (1992) DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Hum Immunol 33:163-173
36. Fleischhauer K, Avila D, Vilbois F, Traversari C, Bordignon C, Wallny HJ (1994) Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain. Tissue Antigens 44:311-317
37. Fleischhauer K, Tanzarella S, Wallny H, Bordignon C, Traversari C (1996) Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/ MART-1 to a peptide-specific HLA-A*0201 + cytotoxic T cell line. J Immunol 157:787-797
38. Fremont DH, Matsumura M, Stura EA, Peterson PA Wilson IA (1992) Crystal structures of two viral peptides in complex with murine MHC class I H-2 kb. Science 257:919-927
39. Fruci D, Rovero P, Falasca G, Chersi A, Sorrentino R, Butler R, Tanigaki N, Tosi R (1993) Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I a chains. Hum Immunol 38:187-192
40. Garcia F, Marina A, Lopez de Castro JA (1997) Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated with ankylosing spondylitis. Tissue Antigens 49:215-221
41. Garcia KC, Teyton L, Wilson IA (1999) Structural basis of T cell recognition. Annu Rev Immunol, 17:369-397
42. Germain RN, Margulies DH (1993) The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403-450
43. Goulder P, Price D, Nowak M, Rowland-Jones S, Phillips R, McMichael A (1997b) Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol Rev 159:17-29
44. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S (1997a) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3:212-217
45. Guo HC, Jardetzky TS, Garrett TP, Lane WS, Strominger JL, Wiley DC (1992) Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature 360:364-366
46. Harrer E, Harrer T, Barbosa P, Feinberg M, Johnson RP, Buchbinder S, Walker BD (1996) Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis 173:476-479
47. Harris PE, Colovai A, Liu Z, Dalla Pavera R, Suciu Foca N (1993) Naturally processed HLA class I bound peptides from c-myc-transfected cells reveal allele-specific motifs. J Immunol 151:5966-5974
48. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905-3910
49. Heck JG (ed) (1994) Heck's pictorial archive of military science, geography and history. Dover Publications, New York
50. Huczko EL, Bodnar WM, Benjamin D, Sakaguchi K, Zhu NZ, Shabanowitz J, Henderson RA, Appella E, Hunt DF, Engelhard VH (1993) Characteristics of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling. J Immunol 151:2572-2587
51. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T (1992) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizaqa M, Sasazuki T (eds) HLA 1991, Proceedings of the Eleventh International Histocompatibility Workshop and Conference, Vol. 1. Oxford University Press, Oxford, pp 1065-1220
52. Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, France del Guercio M, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A (1999) Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA restricted CTL epitopes. J Immunol 162:3915-3925
53. Iwasaki A, Barber BH (1998) Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor. Cancer Immunol Immunother 45:273-279
54. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC (1991) Identification of self peptides bound to purified HLA-B27. Nature 353:326-329
55. Joyce S, Nathenson SG (1994) Methods to study peptides associated with MHC class I molecules. Curr Opin Immunol 6:24-31
56. Kast WM, Brandt RMP, Sidney J, Drijfhout J-W, Kubo RT, Grey HM, Melief CJM, Sette A (1994) The role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 152:3904-3912
57. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Human Immunol 59:1-14
58. Khanna R, Burrows SR, Moss DJ, Silins SL (1996) Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 70:5357-5362
59. Khanna R, Burrows SR, Nicholls J, Poulsen LM (1998) Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 28:451-458
60. Kondo A, Sidney J, Southwood S, del Guercio M-F, Appella E, Sakamoto J, Celis E, Grey HM, Chesnut RW, Kubo RT, Sette A (1995) Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol 155:4307-4312
61. Kondo A, Sidney J, Southwood S, del Guercio MF, Appella E, Sakamoto H, Grey HM, Celis E, Chesnut RW, Kubo RT, Sette A (1997) Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes. Immunogenetics 45:249-258
62. Kowalski H, Erickson AL, Cooper S, Domena JD, Parham P, Walker CM (1996) Patr-A and B, the orthologues of HLA-A and B, present hepatitis C virus epitopes to CDS + cytotoxic T cells from two chronically infected chimpanzees. J Exp Med 183:1761-1775
63. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD (1995) HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 96:2311-2321
64. Krausa P, Brywka M III, Savage D, Hui KM, Bunce M, Ngai JLF, Teo DLT, Ong YW, Barouch D, Allsop CEM, Hill AVS, McMichael AJ, Bodmer JG Browning MJ (1995) Genetic polymorphism within HLA-A*02 : significant allelic variation revealed in different populations. Tissue Antigens 45:223-231
65. Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H, Bodnar WM, Davis TA, Hunt DF (1994) Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 152:3913-3924
66. Le TP, Church LW, Corradin G, Hunter RL, Charoenvit Y, Wang R, de la Vega P, Sacci J, Ballou WR, Kolodny N, Kitov S, Glenn GM, Richards RL, Alving CR, Hoffman SL (1998) Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. Vaccine 16:305-312
67. Madden DR, Garboczi DN, Wiley DC (1993) The antigenic identity of peptide/MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75:693-708
68. Madden DR, Gorga JC, Strominger JL, Wiley DC (1992) The three dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC. Cell 70:1035-1048
69. Maier R, Falk K, Rötzschke O, Maier B, Gnau V, Stevanović S, Jung G, Rammensee HG, Meyerhans A (1994) Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing. Immunogenetics 40:306-308
70. Matsumura M, Fremont DH, Peterson PA, Wilson IA (1992) Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 257:927-934
71. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183:1357-1365
72. McMichael AJ, Phillips RE (1997) Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 15:271-296
73. Melief CJ, Offringa R, Toes RE, Kast WM (1996) Peptide-based cancer vaccines. Curr Opin Immunol 8:651-657
74. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, Houghton M, Fiaccadori F, Ferrari C (1996) Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98:706-714
75. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA (1998) Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160:643-651
76. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG, McAdam S, Klenerman P, Koppe B, Sigmund K, Bangham CR, McMichael AJ (1995) Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 375:606-611
77. Oukka M, Manuguerra JC, Livaditis N, Tourdot S, Riche N, Vergnon I, Cordopatis P, Kosmatopoulos K (1996) Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J Immunol 157:3039-3045
78. Parham P, Adams EJ, Arnett KL (1995) The origins of HLA-A,B,C polymorphism. Immunol Rev 143:141-180
79. Parker KC, Bednarke MA, Hull LK, Utz U, Cunningham B, Zweerink HJ, Biddison WE, Cooligan JE (1992) Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol 149:3580-3587
80. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Y Kawakami (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding peptides. J Immunol 157:2539-2548
81. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, Bangham CR, Phillips RE (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 94:1890-1895
82. Prilliman K, Lindsey M, Zuo Y, Jackson KW, Zhang Y, Hildebrand W (1997) Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501. Immunogenetics 45:379-385
83. Rammensee H-G, Bachmann J, Emmerich N, Stevanović S (1999) SYFPEITHI: an internet database for MHC ligands and peptide motifs. Access via: http://134.2.96.221/scripts/hlaserver.dll/ home.htm
84. Rammensee HG, Friede T, Stevanović S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228
85. Rickinson AB, Moss DJ (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15:405-413
86. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327
87. Rötzschke O, Falk K, Stevanović S, Jung G, Rammensee HG (1992) Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur J Immunol 22:2453-2456
88. Rötzschke O, Falk K, Stevanović S, Gnau V, Jung G, Rammensee HG (1994) Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 39:74-77
89. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A (1993) Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929-937
90. Saper MA, Bjorkman PJ, Wiley DC (1991) Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J Mol Med 219:277-319
91. Sarobe P, Pendleton CD, Akatsuka T, Lau D, Engelhard VH, Feinstone SM, Berzofsky JA (1998) Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 102:1239-1248
92. Schaeffer EB, Sette A, Johnson DL, Bekoff MC, Smith JA, Grey HM, Buus S 1989) Relative contribution of "determinant selection" and "holes in the T-cell repertoire" to T-cell responses. Proc Natl Acad Sci U S A 86:4649-4653
93. Sette A, Grey HM (1992) Chemistry of peptide interactions with MHC proteins. Curr Opin Immunol 4:79-86
94. Sette A, Sidney J (1998) HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10:478-482
95. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio M-F, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586-5592
96. Sidney J, del Guercio MF, Southwood S, Engelhard VH, Appella E, Rammensee HG, Falk K, Rötzschke O, Takiguchi M, Kubo RT, Grey HM, Sette A (1995) Several HLA alleles share overlapping peptide specificities. J Immunol 154:247-259
97. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, del Guercio M-F, Kubo RT, Chesnut RW, Sette A (1996a) Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide binding repertoires of common HLA molecules. Hu Immunol 45:79-93
98. Sidney J, Grey HM, Kubo RT, Sette A (1996b) Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17:261-266
99. Sidney J, Southwood S, del Guercio M-F, Grey HM, Chesnut RW, Kubo RT, Sette A (1996c) Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. J Immunol 157:3480-3490
100. Sidney J, del Guercio MF, Southwood S, Hermanson G, Maewal A, Appella E, Sette A (1997) The HLA-A*0207 peptide binding repertoire is limited to a subset of the A*0201 repertoire. Human Immunol 58:12-20
101. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, Grey HM (1998) The measurement of MHC/peptide interactions by gel infiltration. Curr Protocols Immunol 18.3.1-18.3.19
102. Sinigaglia F, Hammer J (1994) Defining rules for the peptide-MHC class II interaction. Curr Op Immunol 6:52-56
103. Smith KJ, Reid SW, Harlos K, McMichael AJ, Stuart DI, Bell JI, Jones EY (1996b) Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53. Immunity 4:215-228
104. Smith KJ, Reid SW, Stuart DI, McMichael AJ, Jones EY, Bell JI (1996a) An altered position of the a2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Immunity 4:203-213
105. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160:3363-3373
106. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB (1997) Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185:1605-1618
107. Sudo T, Kamikawaji N, Kimura A, Date Y, Savoie CJ, Nakashima H, Furuichi E, Kuhara S, Sasazuki T (1995) Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol 155:4749-4756
108. Thorpe CJ, Travers PJ (1994) Prediction of an HLA-B44 binding motif by the alignment of known epitopes and molecular modeling of the antigen binding cleft. Immunogenetics 40:303-305
109. Threlkeld SC, Wentworth PA, Kalams SA, Wilkes BM, Ruhl DJ, Keogh E, Sidney J, Southwood S, Walker BD, Sette A (1997) Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. J Immunol 159:1648-1657
110. Tourdot S, Oukka M, Manuguerra JC, Magafa V, Vergnon I, Riché N, Bruley-Rosset M, Cordopatis P, Kosmatopoulos K (1997) Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity. J Immunol 159:2391-2398
111. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E (1997) Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 158:1796-1802
112. Van Baalen CA, Klein MR, Huisman RC, Dings MEM, Kerkhof Garde SR, Geretti AM, Gruters R, van Els CACM, Miedema F, Osterhaus ADME (1996) Fine-specificity of cytotoxic T lymphocytes which recognized conserved epitopes of the GAG protein of human immunodeficiency virus type 1. J Gen Virol 77:1659-1665
113. Van der Most RB, Sette A, Oseroff C, Alexander J, Murali-Krishna K, Lau LL, Southwood S, Sidney J, Chesnut WR, Matloubian M, Ahmed R (1996) Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol 157:5543-5554
114. Van Endert PM, Riganelli D, Greco G, Fleischhauer K, Sidney J, Sette A, Bach J-F (1995) The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 182:1883-1895
115. Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186:695-704
116. + T cell-and IFN-gamma-dependent elimination of infected hepatocytes. J Immunol 157:4061-4067
117. Wang R-F, Johnston SL, Southwood S, Sette A, Rosenberg SA (1998) Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA A31 and -A33. J Immunol 160:890-897
118. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, Houghton M, Walker CM (1995) Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sic U S A 92:2755-2759
119. Yewdell JW, Bennink JR (1999) Immunodominance in major histcompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17:51-88
120. Zhang QJ, Gavioli R, Klein G, Masucci MG (1993) An HLA-All-specific motif in nonamer peptides derived from viral and cellular proteins. Proc Natl Acad Sci USA 90:2217-2221